PDF herunterladen
Int J Angiol 2016; 25(01): 044-053
DOI: 10.1055/s-0035-1547527
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Plasma Levels of Advanced Glycation End Products Are Related to the Clinical Presentation and Angiographic Severity of Symptomatic Lower Extremity Peripheral Arterial Disease

Anand Prasad
1   Division of Cardiology, Department of Medicine, The University of Texas Health Science Center San Antonio, San Antonio, Texas
2   Department of Medicine, The University of California San Diego, La Jolla, California
,
James R. Lane
2   Department of Medicine, The University of California San Diego, La Jolla, California
,
Sotirios Tsimikas
2   Department of Medicine, The University of California San Diego, La Jolla, California
,
Ehtisham Mahmud
2   Department of Medicine, The University of California San Diego, La Jolla, California
,
Srikrishna Khandrika
2   Department of Medicine, The University of California San Diego, La Jolla, California
,
Peter Bekker
2   Department of Medicine, The University of California San Diego, La Jolla, California
,
Manjusha Ilapakurti
2   Department of Medicine, The University of California San Diego, La Jolla, California
,
Dan Nguyen
2   Department of Medicine, The University of California San Diego, La Jolla, California
,
Amir Ravandi
3   The Institute of Cardiovascular Sciences, St. Boniface General Hospital, Winnipeg, Manitoba, Canada
,
Travis Israel
2   Department of Medicine, The University of California San Diego, La Jolla, California
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
23. März 2015 (online)

    Lizenzen und Reprints

Abstract

Evidence implicates a role of advanced glycation end products (AGEs) in the development of atherosclerosis. The present study examined the relationship between plasma levels of AGEs and the clinical and angiographic characteristics of patients with symptomatic peripheral arterial disease (PAD). A total of 40 consecutive patients with symptomatic lower extremity PAD undergoing invasive evaluation were enrolled. Clinical history, angiographic data, and plasma levels of total AGE (tAGE), Nʹ-carboxymethyllysine (CML), and high-sensitivity C-reactive protein were obtained. In multivariate analyses, there were independent relationships noted between tAGE levels and the presence of critical limb ischemia (CLI) (r 2 = 0.195, p = 0.003), Rutherford stage (r 2 = 0.351, p < 0.001), and the average below the knee (BTK) score (r 2 = 0.119, p = 0.006). Presence of CLI (r 2 = 0.154, p = 0.012) and the Rutherford stage (r 2 = 0.194, p = 0.003) were associated with CML levels. We demonstrate a relationship between tAGE and the symptom profile of patients with PAD and an association between tAGE and infrapopliteal angiographic disease severity. Both tAGE and CML levels were related to the presence of CLI. These data suggest that AGE levels may reflect the severity of PAD and may be of importance in CLI.

Keywords

peripheral arterial disease - advanced glycation - critical limb ischemia - atherosclerosis
 

  • References

  • 1 Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999; 22 (9) 1543-1548
    CrossrefPubMedGoogle Scholar
  • 2 Kilhovd BK, Juutilainen A, Lehto S , et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 2005; 25 (4) 815-820
    CrossrefPubMedGoogle Scholar
  • 3 Kilhovd BK, Juutilainen A, Lehto S , et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 2007; 50 (7) 1409-1417
    CrossrefPubMedGoogle Scholar
  • 4 Nin JW, Jorsal A, Ferreira I , et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011; 34 (2) 442-447
    CrossrefPubMedGoogle Scholar
  • 5 Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H. Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 2001; 85 (1) 87-91
    CrossrefPubMedGoogle Scholar
  • 6 Mulder DJ, van Haelst PL, Graaff R, Gans RO, Zijlstra F, Smit AJ. Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. Neth Heart J 2009; 17 (4) 162-168
    CrossrefPubMedGoogle Scholar
  • 7 [Anonymous] National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25) 3143-3421
    PubMedGoogle Scholar
  • 8 Lapolla A, Piarulli F, Sartore G , et al. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 2007; 30 (3) 670-676
    CrossrefPubMedGoogle Scholar
  • 9 Takahashi R, Imamura A, Yoshikane M , et al. High serum concentrations of pentosidine, an advanced glycation end product, are associated with low normal value of ankle-brachial index in apparently healthy men. Metabolism 2011; 60 (5) 649-654
    CrossrefPubMedGoogle Scholar
  • 10 Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31 (1 Pt 2) S1-S296
    CrossrefPubMedGoogle Scholar
  • 11 Allison MA, Hiatt WR, Hirsch AT, Coll JR, Criqui MH. A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life. J Am Coll Cardiol 2008; 51 (13) 1292-1298
    CrossrefPubMedGoogle Scholar
  • 12 Willenberg T, Diehm N, Zwahlen M , et al. Impact of long-term corticosteroid therapy on the distribution pattern of lower limb atherosclerosis. Eur J Vasc Endovasc Surg 2010; 39 (4) 441-446
    CrossrefPubMedGoogle Scholar
  • 13 Quigley FG, Faris IB, Duncan HJ. A comparison of Doppler ankle pressures and skin perfusion pressure in subjects with and without diabetes. Clin Physiol 1991; 11 (1) 21-25
    CrossrefPubMedGoogle Scholar
  • 14 Stein R, Hriljac I, Halperin JL, Gustavson SM, Teodorescu V, Olin JW. Limitation of the resting ankle-brachial index in symptomatic patients with peripheral arterial disease. Vasc Med 2006; 11 (1) 29-33
    CrossrefPubMedGoogle Scholar
  • 15 Suzuki E, Yoshimura T, Omura Y , et al. Higher arterial stiffness, greater peripheral vascular resistance and lower blood flow in lower-leg arteries are associated with long-term hyperglycaemia in type 2 diabetic patients with normal ankle-brachial index. Diabetes Metab Res Rev 2009; 25 (4) 363-369
    CrossrefPubMedGoogle Scholar
  • 16 de Vos LC, Noordzij MJ, Mulder DJ , et al. Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease. Arterioscler Thromb Vasc Biol 2013; 33 (1) 131-138
    CrossrefPubMedGoogle Scholar
  • 17 Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006; 113 (22) 2623-2629
    CrossrefPubMedGoogle Scholar
  • 18 Faglia E. Characteristics of peripheral arterial disease and its relevance to the diabetic population. Int J Low Extrem Wounds 2011; 10 (3) 152-166
    CrossrefPubMedGoogle Scholar
  • 19 Huijberts MS, Schaper NC, Schalkwijk CG. Advanced glycation end products and diabetic foot disease. Diabetes Metab Res Rev 2008; 24 (Suppl. 01) S19-S24
    CrossrefPubMedGoogle Scholar
  • 20 Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci 2005; 1043: 598-604
    CrossrefPubMedGoogle Scholar
  • 21 Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114 (6) 597-605
    CrossrefPubMedGoogle Scholar
  • 22 Prasad A, Bekker P, Tsimikas S. Advanced glycation end products and diabetic cardiovascular disease. Cardiol Rev 2012; 20 (4) 177-183
    CrossrefPubMedGoogle Scholar
  • 23 Negrean M, Stirban A, Stratmann B , et al. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007; 85 (5) 1236-1243
    PubMedGoogle Scholar
  • 24 Vlassara H, Cai W, Crandall J , et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 2002; 99 (24) 15596-15601
    CrossrefPubMedGoogle Scholar
  • 25 Nakamura Y, Horii Y, Nishino T , et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 143 (6) 1649-1656
    PubMedGoogle Scholar
  • 26 Halushka MK, Selvin E, Lu J, Macgregor AM, Cornish TC. Use of human vascular tissue microarrays for measurement of advanced glycation endproducts. J Histochem Cytochem 2009; 57 (6) 559-566
    CrossrefPubMedGoogle Scholar
  • 27 Peppa M, Brem H, Ehrlich P , et al. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 2003; 52 (11) 2805-2813
    CrossrefPubMedGoogle Scholar
  • 28 Peppa M, Raptis SA. Glycoxidation and wound healing in diabetes: an interesting relationship. Curr Diabetes Rev 2011; 7 (6) 416-425
    CrossrefPubMedGoogle Scholar
  • 29 Goova MT, Li J, Kislinger T , et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159 (2) 513-525
    CrossrefPubMedGoogle Scholar
  • 30 Schurman L, McCarthy AD, Sedlinsky C , et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 2008; 116 (6) 333-340
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 31 Koschinsky T, He CJ, Mitsuhashi T , et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 1997; 94 (12) 6474-6479
    CrossrefPubMedGoogle Scholar
  • 32 Uribarri J, Woodruff S, Goodman S , et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110 (6) 911-16.e12
    CrossrefPubMedGoogle Scholar